Adderall XR Switching Protocols: How to Switch From or To Other ADHD Stimulants

How Adderall XR Works: Mechanism Before You Switch

Adderall XR is a capsule containing two bead populations: 50% immediate-release and 50% delayed-release mixed amphetamine salts. This produces a biphasic plasma curve with peaks at roughly 3 hours and 7 hours after ingestion 1. Understanding this pharmacokinetic profile matters because the drug you switch to may have a very different release pattern.

The active ingredient is a mixture of four amphetamine salts (amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, dextroamphetamine sulfate) at a 3:1 ratio of d-amphetamine to l-amphetamine. Both enantiomers block reuptake of dopamine and norepinephrine at presynaptic transporters, but d-amphetamine also promotes vesicular release of dopamine into the synapse 2. The l-enantiomer contributes a stronger noradrenergic effect relative to its dopaminergic activity.

This dual-enantiomer composition distinguishes Adderall XR from pure dextroamphetamine products like Dexedrine and from the prodrug lisdexamfetamine (Vyvanse), which converts exclusively to d-amphetamine after enzymatic cleavage in red blood cells 3. The clinical implication: patients who respond well to the l-amphetamine component may notice a different side-effect or efficacy profile when switched to a pure d-amphetamine product, even at theoretically equivalent doses.

Why Clinicians Switch: The 30% Rule

Roughly 30% of ADHD patients started on a first-line stimulant will require a medication change within the first year of treatment 4. The MTA Cooperative Group Study (N=579), published in the Archives of General Psychiatry in 1999, demonstrated that carefully titrated stimulant medication was superior to behavioral therapy alone and to routine community care for core ADHD symptoms. But the study also showed that optimal outcomes required individualized dose adjustments and, often, trials of more than one agent.

The most common reasons to switch include:

• Appetite suppression or weight loss exceeding 5% of baseline body weight
• Insomnia persisting beyond the first two weeks of treatment
• Rebound irritability in the late afternoon as the drug wears off
• Cardiovascular concerns such as resting heart rate increases above 100 bpm
• Inadequate duration of coverage (e.g., Adderall XR wearing off by 3 PM in a patient who needs coverage until 6 PM)
• Insurance or formulary restrictions mandating a switch to a preferred agent
• Partial response after adequate dose titration, defined by the American Academy of Pediatrics (AAP) as <50% reduction in symptom rating scales after trial at maximum tolerated dose 5

The AAP's 2019 clinical practice guideline recommends: "If the patient does not adequately respond to one stimulant medication, the clinician should recommend a trial of a medication in the other stimulant class" 5. This means moving from an amphetamine (like Adderall XR) to a methylphenidate (like Concerta), or vice versa, before considering non-stimulants.

Dose-Equivalence Table: Amphetamine to Methylphenidate Conversions

The single most important number for any stimulant switch is the potency ratio. A widely used clinical approximation holds that 1 mg of amphetamine base produces effects roughly equivalent to 2 mg of methylphenidate 6. This ratio is approximate. Individual pharmacogenomic variation in CYP2D6 and catechol-O-methyltransferase (COMT) activity can shift effective potency by 20-40% in either direction.

Practical conversion examples using the 2:1 methylphenidate-to-amphetamine ratio:

| Current Adderall XR dose | Approximate Concerta equivalent | Approximate Ritalin LA equivalent | |---|---|---| | 10 mg | 18-27 mg | 20 mg | | 20 mg | 36 mg | 40 mg | | 30 mg | 54 mg | 60 mg | | 40 mg | 72 mg | 60-80 mg |

These conversions are starting points. Dr. Thomas Spencer of Massachusetts General Hospital noted in a review of stimulant pharmacotherapy that "dose-equivalence tables should guide initial conversion, but clinical titration to the individual patient's optimal dose remains essential" 7.

For within-family amphetamine switches (Adderall XR to Vyvanse, Adderall XR to Dexedrine), the conversions differ because Vyvanse delivers only d-amphetamine while Adderall XR delivers both d- and l-amphetamine. Published guidance from Shire/Takeda and clinical experience suggest these approximate equivalences:

| Adderall XR dose | Vyvanse equivalent | Dexedrine Spansule equivalent | |---|---|---| | 10 mg | 30 mg | 10 mg | | 20 mg | 50-60 mg | 15-20 mg | | 30 mg | 70 mg | 20-25 mg |

Switching Within the Amphetamine Family: Adderall XR to Vyvanse

The Adderall XR-to-Vyvanse switch is the most frequently performed within-class conversion in ADHD practice. Both are amphetamine-based, but they differ in three clinically meaningful ways.

First, Vyvanse (lisdexamfetamine) is a prodrug. It requires enzymatic hydrolysis by aminopeptidases in red blood cells to release active d-amphetamine 3. This prodrug mechanism produces a smoother plasma curve with less peak-trough variation compared to Adderall XR's bead-based delivery system. Patients who experience sharp "on-off" transitions with Adderall XR often report a gentler onset and offset with Vyvanse.

Second, Vyvanse delivers only d-amphetamine. Patients who derive benefit from Adderall XR's l-amphetamine component (which preferentially affects norepinephrine) may notice reduced peripheral activation but potentially less efficacy for inattentive symptoms.

Third, Vyvanse has a longer effective duration. Clinical trials demonstrated a mean duration of efficacy of approximately 13 hours for Vyvanse 70 mg, compared to roughly 10-12 hours for Adderall XR at equivalent doses 8.

Protocol: Stop Adderall XR on day 1. Start Vyvanse on day 2 at the equivalent dose from the table above. No washout period is needed. If the patient was on Adderall XR 20 mg, begin Vyvanse at 50 mg and re-evaluate at 2-4 weeks.

Switching Across Stimulant Families: Adderall XR to Methylphenidate Products

Crossing from the amphetamine family to the methylphenidate family is the recommended second step when a patient fails an adequate amphetamine trial. Methylphenidate blocks dopamine and norepinephrine reuptake at the transporter level but, unlike amphetamine, does not significantly promote vesicular monoamine release 9. This mechanistic difference explains why approximately 25-30% of patients who fail one stimulant class will respond to the other 10.

Adderall XR to Concerta (methylphenidate OROS): Concerta uses an osmotic-release oral system (OROS) that delivers 22% of the total dose as an immediate-release overcoat and 78% via osmotic push over approximately 10-12 hours. Apply the 2:1 ratio. A patient on Adderall XR 20 mg starts Concerta at 36 mg. Concerta is available in 18 mg, 27 mg, 36 mg, and 54 mg strengths, so dose matching may require rounding.

Adderall XR to Ritalin LA (methylphenidate extended-release): Ritalin LA uses a bead-based system similar to Adderall XR, with 50% immediate-release and 50% delayed-release beads. The switch is conceptually simpler because both drugs share a biphasic release profile. Convert at the 2:1 ratio (Adderall XR 20 mg → Ritalin LA 40 mg).

Adderall XR to Daytrana (methylphenidate transdermal patch): The methylphenidate patch delivers drug through the skin over 9 hours of wear time, with effects lasting up to 12 hours. Dose conversions are less precise because transdermal bioavailability varies with patch site, skin temperature, and individual absorption. Start with the lowest patch strength (10 mg/9 hr) regardless of the prior Adderall XR dose, then titrate upward 11.

For all cross-family switches, an overnight conversion is standard. The patient takes their last Adderall XR dose on one day and starts the new methylphenidate product the next morning. A simultaneous taper-titration (running both agents concurrently) is not recommended because additive dopaminergic stimulation raises the risk of insomnia, tachycardia, and anxiety without clinical benefit.

Switching From Methylphenidate to Adderall XR

The reverse conversion, methylphenidate to Adderall XR, follows the same 2:1 ratio in the opposite direction. A patient on Concerta 54 mg would start Adderall XR at approximately 25-30 mg. Since Adderall XR is available in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules, the clinician would typically choose 25 mg or 30 mg depending on clinical context.

A 2004 randomized crossover trial by Faraone and colleagues compared Adderall XR and methylphenidate OROS head-to-head in 58 adults with ADHD. Adderall XR showed a larger effect size for inattention symptoms (d=0.77 vs. d=0.48), though both treatments were effective and well-tolerated 12. This finding, along with data from the CADDRA (Canadian ADHD Resource Alliance) guidelines, supports the clinical observation that some patients have a clear amphetamine or methylphenidate preference that can only be determined by trial.

Regarding the switch itself, the CADDRA practice guideline advises: "When switching between stimulant classes, use published equipotent dose tables as a starting point and titrate based on clinical response over 2 to 4 weeks" 13.

Special Situations: Switching Adderall IR to Adderall XR

Not all switches involve a different molecule. Converting from immediate-release Adderall (taken two or three times daily) to Adderall XR (once daily) is one of the most common ADHD medication changes. The FDA-approved labeling states that Adderall XR at a given total daily dose is designed to produce equivalent plasma levels to the same total daily dose of immediate-release Adderall given in two divided doses 1.

The conversion is 1:1 by total daily dose. A patient taking Adderall IR 10 mg twice daily (20 mg total) switches to Adderall XR 20 mg once daily. No titration period is needed. However, patients taking IR three times daily may find that XR does not provide adequate late-afternoon coverage, as XR's second peak occurs around hour 7 while a third IR dose would have been taken around hour 8-10. In these cases, clinicians may prescribe Adderall XR in the morning plus a small IR booster (5-10 mg) in the early afternoon.

Monitoring After a Switch

Every stimulant switch requires structured follow-up. The Texas Children's Medication Algorithm Project (TMAP) recommends reassessment at 1-2 weeks post-switch and again at 4-6 weeks to capture both acute tolerability and steady-state efficacy 14.

At each follow-up, the clinician should evaluate:

• ADHD symptom scales (ASRS for adults, Vanderbilt for children) comparing pre-switch and post-switch scores
• Vital signs including resting heart rate and blood pressure, as amphetamines and methylphenidates differ in their cardiovascular profiles
• Appetite and weight, recorded objectively rather than by patient estimate
• Sleep onset latency, which can shift significantly between stimulant types; a 2012 meta-analysis found that methylphenidate was associated with a weighted mean sleep onset delay of 0.6 hours compared to 0.9 hours for amphetamines 15
• Mood and emotional lability, particularly in pediatric patients during the first 2 weeks

If the new agent produces equivalent symptom control with fewer side effects, maintain the dose. If symptom control is inadequate after 4 weeks at the maximum tolerated dose of the second stimulant, the AAP guideline recommends considering a non-stimulant adjunct (atomoxetine, guanfacine XR, or clonidine XR) or referral to a specialist 5.

Pharmacogenomics and Switch Decisions

Genetic testing for CYP2D6, COMT Val158Met, and dopamine transporter (DAT1) polymorphisms is increasingly available, though not yet standard of care. A 2019 systematic review identified CYP2D6 ultrarapid metabolizers as having faster amphetamine clearance, which may explain inadequate duration of effect at standard doses 16. COMT Val/Val carriers tend to have lower baseline synaptic dopamine and may respond preferentially to amphetamines over methylphenidate.

These genetic markers do not yet have sufficient evidence to dictate first-line therapy selection. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has not issued a guideline for ADHD stimulants as of 2026. Pharmacogenomic panels can, however, be informative after a patient has failed two stimulant trials and the clinician is choosing between a third stimulant trial versus a non-stimulant.

Patients on Adderall XR 30 mg or higher who report rapid symptom return (within 5-6 hours) despite the extended-release formulation should be evaluated for CYP2D6 ultrarapid metabolism before being switched to another agent, as the problem may be pharmacokinetic rather than pharmacodynamic.